Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTI-TREX
2024-513650-30-00Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in Graft Thrombosis and thromboprophylaxis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Anti-Xa activity within target range at 28-30 hours. Started Jul 2024; status: completed.
02
Drugs
enoxaparin
03
Conditions
Graft Thrombosisthromboprophylaxis
Beyond the preview
Go deeper on 2024-513650-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513650-30-00.